Literature DB >> 21985171

Apixaban: first global approval.

Julia Watson1, Glen Whiteside, Caroline Perry.   

Abstract

Apixaban (Eliquis™), an oral direct factor Xa inhibitor, is being developed by Bristol-Myers Squibb and Pfizer as a therapy for the prevention and/or treatment of thrombotic disorders. Apixaban has been approved in the EU for the prevention of venous thromboembolism (VTE) after hip or knee replacement. A rolling submission for approval of apixaban for the prevention of stroke in patients with atrial fibrillation has also been initiated in the US. Worldwide phase III development of apixaban is underway for the prevention and treatment of VTE, and prevention of stroke in patients with atrial fibrillation. Development for acute coronary syndromes has been stopped following the discontinuation of the phase III APPRAISE-II trial. This article summarizes the milestones in the development of apixaban leading to this first approval for the prevention of VTE after hip or knee replacement.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21985171     DOI： 10.2165/11596820-000000000-00000

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


  16 in total

1.  Quantification of apixaban's therapeutic utility in prevention of venous thromboembolism: selection of phase III trial dose.

Authors:  T A Leil; Y Feng; L Zhang; A Paccaly; P Mohan; M Pfister
Journal:  Clin Pharmacol Ther       Date:  2010-08-04       Impact factor: 6.875

2.  Apixaban versus enoxaparin for thromboprophylaxis after hip replacement.

Authors:  Michael Rud Lassen; Alexander Gallus; Gary E Raskob; Graham Pineo; Dalei Chen; Luz Margarita Ramirez
Journal:  N Engl J Med       Date:  2010-12-23       Impact factor: 91.245

3.  Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial.

Authors:  Michael Rud Lassen; Gary E Raskob; Alexander Gallus; Graham Pineo; Dalei Chen; Philip Hornick
Journal:  Lancet       Date:  2010-03-06       Impact factor: 79.321

4.  Apixaban with antiplatelet therapy after acute coronary syndrome.

Authors:  John H Alexander; Renato D Lopes; Stefan James; Rakhi Kilaru; Yaohua He; Puneet Mohan; Deepak L Bhatt; Shaun Goodman; Freek W Verheugt; Marcus Flather; Kurt Huber; Danny Liaw; Steen E Husted; Jose Lopez-Sendon; Raffaele De Caterina; Petr Jansky; Harald Darius; Dragos Vinereanu; Jan H Cornel; Frank Cools; Dan Atar; Jose Luis Leiva-Pons; Matyas Keltai; Hisao Ogawa; Prem Pais; Alexander Parkhomenko; Witold Ruzyllo; Rafael Diaz; Harvey White; Mikhail Ruda; Margarida Geraldes; Jack Lawrence; Robert A Harrington; Lars Wallentin
Journal:  N Engl J Med       Date:  2011-07-24       Impact factor: 91.245

5.  Apixaban decreases coagulation activity in patients with acute deep-vein thrombosis.

Authors:  Yu Chen Barrett; Jessie Wang; Robert Knabb; Puneet Mohan
Journal:  Thromb Haemost       Date:  2010-10-12       Impact factor: 5.249

6.  Apixaban or enoxaparin for thromboprophylaxis after knee replacement.

Authors:  Michael Rud Lassen; Gary E Raskob; Alexander Gallus; Graham Pineo; Dalei Chen; Ronald J Portman
Journal:  N Engl J Med       Date:  2009-08-06       Impact factor: 91.245

7.  Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study.

Authors:  H Buller; D Deitchman; M Prins; A Segers
Journal:  J Thromb Haemost       Date:  2008-06-06       Impact factor: 5.824

8.  Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial.

Authors:  John H Alexander; Richard C Becker; Deepak L Bhatt; Frank Cools; Filippo Crea; Mikael Dellborg; Keith A A Fox; Shaun G Goodman; Robert A Harrington; Kurt Huber; Steen Husted; Basil S Lewis; Jose Lopez-Sendon; Puneet Mohan; Gilles Montalescot; Mikhail Ruda; Witold Ruzyllo; Freek Verheugt; Lars Wallentin
Journal:  Circulation       Date:  2009-05-26       Impact factor: 29.690

9.  Apixaban metabolism and pharmacokinetics after oral administration to humans.

Authors:  Nirmala Raghavan; Charles E Frost; Zhigang Yu; Kan He; Haiying Zhang; W Griffith Humphreys; Donald Pinto; Shiangyuan Chen; Samuel Bonacorsi; Pancras C Wong; Donglu Zhang
Journal:  Drug Metab Dispos       Date:  2008-10-02       Impact factor: 3.922

10.  Arterial antithrombotic and bleeding time effects of apixaban, a direct factor Xa inhibitor, in combination with antiplatelet therapy in rabbits.

Authors:  P C Wong; C A Watson; E J Crain
Journal:  J Thromb Haemost       Date:  2008-07-19       Impact factor: 5.824
View more
  7 in total

1.  [Non-vitamin K dependent oral anticoagulants : What is important in intensive care medicine].

Authors:  D C Gulba; L Broscaru
Journal:  Med Klin Intensivmed Notfmed       Date:  2017-01-31       Impact factor: 0.840

Review 2.  Recent progress and market analysis of anticoagulant drugs.

Authors:  Ping Fan; Yangyang Gao; Minglin Zheng; Ting Xu; Paul Schoenhagen; Zhaohui Jin
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

Review 3.  New oral anticoagulants: a review of the literature with particular emphasis on patients with impaired renal function.

Authors:  Birgitte Klindt Poulsen; Erik Lerkevang Grove; Steen Elkjaer Husted
Journal:  Drugs       Date:  2012-09-10       Impact factor: 9.546

Review 4.  Prevention of venous thromboembolism with new oral anticoagulants versus standard pharmacological treatment in acute medically ill patients: a systematic review and meta-analysis.

Authors:  Ida Ehlers Albertsen; Torben Bjerregaard Larsen; Lars Hvilsted Rasmussen; Thure Filskov Overvad; Gregory Y H Lip
Journal:  Drugs       Date:  2012-09-10       Impact factor: 9.546

Review 5.  Apixaban: a review of its use in the prevention of venous thromboembolism after knee or hip replacement surgery.

Authors:  Emma D Deeks
Journal:  Drugs       Date:  2012-06-18       Impact factor: 9.546

Review 6.  Safety of new oral anticoagulant drugs: a perspective.

Authors:  Juan Antonio Vílchez; Pilar Gallego; Gregory Y H Lip
Journal:  Ther Adv Drug Saf       Date:  2014-02

7.  Determination of rivaroxaban, apixaban and edoxaban in rat plasma by UPLC-MS/MS method.

Authors:  Wan-Li Zhang; Dan Lou; Dong-Tao Zhang; Yin Zhang; Huan-Jie Huang
Journal:  J Thromb Thrombolysis       Date:  2016-08       Impact factor: 2.300
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.